Physician profile
Daniel Mora Rivera
NPI 1275578726
$3,769.53
in general payments reported to CMS, 2019-2025
23 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.03 · 2022: $894 · 2023: $1,275 · 2024: $873 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.96 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $837.93 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $394.43 | 2020-2025 | |
| Astellas Pharma US INC | $294.14 | 2022-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $227.61 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.51 | 2022-2025 | Jardiance |
| Abbott Laboratories | $195.65 | 2023-2025 | Proclaim, Freestyle Libre 3 |
| Abbvie INC. | $189.51 | 2022-2025 | |
| Lilly USA, LLC | $184.98 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $162.00 | 2022 | |
| Glaxosmithkline, LLC. | $156.90 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $148.64 | 2022-2025 | |
| Exact Sciences Corporation | $123.66 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $113.39 | 2022-2025 | Otezla, Repatha, Repatha |
| Intuity Medical INC | $112.28 | 2022 | |
| Merck Sharp & Dohme LLC | $85.00 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.15 | 2024-2025 | Xifaxan, Trulance |
| Dynavax Technologies Corporation | $59.52 | 2022-2025 | Heplisav-B |
| Xeris Pharmaceuticals, INC. | $46.30 | 2023 | Keveyis |
| Novartis Pharmaceuticals Corporation | $44.27 | 2023 | |
| Sanofi-Aventis U.S. LLC | $25.84 | 2024 | |
| Phathom Pharmaceuticals, INC. | $22.64 | 2024 | Voquezna |
| Hologic Sales and Service, LLC | $18.30 | 2023 | Thinprep 2000 Processor, Aptima |
| Otsuka America Pharmaceutical, INC. | $17.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mora Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.